Based on the datasets of the Kaplan–Meier plotter, we observed that high expression of TXNIP was associated with poor clinical outcomes of OS and PPS for gastric cancer, especially in subgroup analysis of “stage 2 to 4”, “lauren classification/intestinal/diffuse” and “treatment/surgery alone” (Additional file 8: Table S2). Here, TXNIP is linked to gastric cancer.